SCHEMBL14184941

SCHEMBL14184941

Cc1cc2nc(-c3cc(NC(=O)Cc4ccc5ccccc5c4)n[nH]3)[nH]c2cc1C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 3/20 0.60
FOXO1 Q12778 7/20 0.60
CCNB2 O95067 1/20 0.54
CCNE2 O96020 1/20 0.54
CDK1 P06493 1/20 0.54
CCNB1 P14635 1/20 0.54
CCNA2 P20248 1/20 0.54
CCNE1 P24864 1/20 0.54
CDK2 P24941 1/20 0.54
CCNA1 P78396 1/20 0.54
CDK5 Q00535 1/20 0.54
CDK5R1 Q15078 1/20 0.54
CCNB3 Q8WWL7 1/20 0.54
RIOK2 Q9BVS4 5/20 0.50
GSK3A P49840 3/20 0.50
MAPK10 P53779 3/20 0.50
MAPK8 P45983 1/20 0.50
HIPK1 Q86Z02 1/20 0.50
SNRK Q9NRH2 1/20 0.50
PDE10A Q9Y233 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13373176 0.90 FOXO1 (0.58) NPY5RFOXO1CCNA2CDK2CCNA1
SCHEMBL13373143 0.88 FOXO1 (0.57) NPY5RFOXO1CCNA2CCNE1CDK2
SCHEMBL13373225 0.83 FOXO1 (0.64) FOXO1PDE10A
SCHEMBL13373160 0.82 MMP2 (0.54) NPY5RFOXO1PDE10A
SCHEMBL13373181 0.80 PDE10A (0.55) NPY5RFOXO1PDE10A
SCHEMBL13373250 0.78 PDE10A (0.47) FOXO1PDE10A
SCHEMBL6584827 0.78 NPY5R (0.64) NPY5RCCNB2CCNE2CDK1CCNB1
SCHEMBL13374845 0.78 FOXO1 (0.52) FOXO1PDE10A
SCHEMBL13375029 0.77 HPSE (0.62) FOXO1PDE10A
SCHEMBL6586717 0.76 NPY5R (0.71) NPY5RCCNB2CCNE2CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080125418-A1 Benzimidazole derivatives and their use as kdr kinase protein inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-29 US disclosed
US-20080125418-A1 Benzimidazole derivatives and their use as kdr kinase protein inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125418-A1 Benzimidazole derivatives and their use as kdr kinase protein inhibitors KDR, MUSK, FLT4 NPY5R 602/4885FOXO1 455/4885CCNB2 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.